| Triple-negative breast cancer: promising prognostic biomarkers currently in development J Sukumar, K Gast, D Quiroga, M Lustberg, N Williams Expert review of anticancer therapy 21 (2), 135-148, 2021 | 175 | 2021 |
| Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development B Benner, L Good, D Quiroga, TE Schultz, M Kassem, WE Carson, ... Drug design, development and therapy, 1693-1704, 2020 | 139 | 2020 |
| Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens SS Seregin, DPW Rastall, I Evnouchidou, CF Aylsworth, D Quiroga, ... Autoimmunity 46 (8), 497-508, 2013 | 80 | 2013 |
| Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells YA Aldhamen, Y Pepelyayeva, DPW Rastall, SS Seregin, E Zervoudi, ... Journal of innate immunity 7 (3), 275-289, 2015 | 51 | 2015 |
| Deficient mismatch repair and the role of immunotherapy in metastatic colorectal cancer D Quiroga, HK Lyerly, MA Morse Current treatment options in oncology 17, 1-16, 2016 | 49 | 2016 |
| A New Adenovirus Based Vaccine Vector Expressing an Eimeria tenella Derived TLR Agonist Improves Cellular Immune Responses to an Antigenic Target DM Appledorn, YA Aldhamen, W DePas, SS Seregin, CJJ Liu, N Schuldt, ... PLoS One 5 (3), e9579, 2010 | 43 | 2010 |
| TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo SS Seregin, YA Aldhamen, DM Appledorn, CF Aylsworth, S Godbehere, ... PloS one 6 (7), e22064, 2011 | 21 | 2011 |
| Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis D Quiroga, DA Liebner, JS Philippon, S Hoffman, Y Tan, JL Chen, ... BMC cancer 20, 1-11, 2020 | 20 | 2020 |
| Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer JS Sukumar, D Quiroga, M Kassem, M Grimm, NV Shinde, L Appiah, ... Breast cancer research and treatment, 1-6, 2021 | 17 | 2021 |
| Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer R Wesolowski, A Stiff, D Quiroga, C McQuinn, Z Li, H Nitta, H Savardekar, ... BMC cancer 20, 1-12, 2020 | 15 | 2020 |
| Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy D Spakowicz, R Hoyd, M Husain, G Tinoco, SH Patel, JT Burkart, ... age (mean (sd) 62, 13.26, 2019 | 7 | 2019 |
| Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase H Savardekar, C Allen, H Jeon, J Li, D Quiroga, E Schwarz, RC Wu, ... Molecular Cancer Research 22 (3), 308-321, 2024 | 5 | 2024 |
| Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor EL McMichael, NB Courtney, MC Duggan, R Wesolowski, D Quiroga, ... Oncoimmunology 6 (5), e1312045, 2017 | 5 | 2017 |
| Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination D Quiroga, YA Aldhamen, DM Appledorn, S Godbehere, A Amalfitano Cancer Immunology, Immunotherapy 64, 479-491, 2015 | 5 | 2015 |
| Clinical markers of immunotherapy outcomes in advanced sarcoma M Husain, D Quiroga, HG Kim, S Lenobel, M Xu, H Iwenofu, JL Chen, ... BMC cancer 23 (1), 326, 2023 | 4 | 2023 |
| Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer–a review of current evidence for and against the use of anti-HER2 treatment regimens KCC Johnson, D Quiroga, P Sudheendra, R Wesolowski Expert review of anticancer therapy 22 (5), 505-522, 2022 | 4 | 2022 |
| A pilot study of Bruton’s tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors. B Benner, DM Quiroga, L Good, S Sun, H Savardekar, MC Duggan, ... Journal of Clinical Oncology 38 (15_suppl), 3111-3111, 2020 | 4 | 2020 |
| Axillary Management: How Much Is Too Much? N Owusu-Brackett, B Facer, D Quiroga, A Pariser, M Grimm, S Beyer, ... Current oncology reports, 1-9, 2024 | 2 | 2024 |
| Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer NO Williams, D Quiroga, C Johnson, A Brufsky, M Chambers, ... Therapeutic Advances in Medical Oncology 15, 17588359231217976, 2023 | 2 | 2023 |
| The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer KCC Johnson, D Goldstein, J Tharakan, D Quiroga, M Kassem, M Grimm, ... Oncology and Therapy 11 (3), 361-374, 2023 | 2 | 2023 |
William CarsonProfessor of Surgery, Ohio State UniversityПодтвержден адрес электронной почты в домене osumc.edu